SLC5A2 and heart failure: Based on the results of recent CV outcome studies, GLP-1RA drugs compared with sodium–glucose cotransporter 2 (SGLT2) inhibitors have shown, in addition to some common favorable CV effects, several class-specific effects (GLP-1RA: benefits for the risk of atherosclerotic outcomes, inhibitors SGLT2: benefits for the risk of heart failure outcomes) contributing to the overall improvement of CV.